MiguelA.VillalonaMDFACP, FAAAS

Oncology • Duarte, CA

Thoracic Cancer

Director Early Phase Therapeutics

Join to view full profile

Dr. Villalona is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Villalona's full profile

Already have an account?

Office
Medical Oncology and Therapeutics Research
1500 East Duarte Road
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-218-8233
Is this information wrong?

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1995
University at BuffaloFellowship, Hematology and Medical Oncology, 1990 - 1992
University of MinnesotaFellowship, Hematology and Medical Oncology, 1989 - 1990
SUNY Health Science Center at BrooklynResidency, Internal Medicine, 1986 - 1989
Universidad Nacional Pedro Henriquez UrenaClass of 1985

Certifications & Licensure

FL State Medical License 1998 - 2025
CA State Medical License 2020 - 2024
KY State Medical License 2020 - 2021
OH State Medical License 1999 - 2017
TX State Medical License 1995 - 2010
AL State Medical License Active through 1996
MN State Medical License 1989 - 1994
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow American Association for the Advancement of Science
Fellow American College of Physicians
Premio Fray Anton de Montesinos Asociacion de egresados UASD NYC
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Join now to see all

Clinical Trials

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 2
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors Start of enrollment: 2000 Nov 01
Completed
Phase 1
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma Start of enrollment: 2001 Jul 01
Completed
Phase 1, Phase 2
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer Start of enrollment: 2005 Oct 01
Completed
Phase 2
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Oct 01
Terminated
Phase 2
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation Start of enrollment: 2009 Mar 01
Completed
Phase 2
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors Start of enrollment: 2017 Nov 03
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.
Ting Lu, Rui Ma, Anthony G Mansour, Christian Bustillos, Zhiyao Li, Zhenlong Li, Shoubao Ma, Kun-Yu Teng, Hanyu Chen, Jianying Zhang, Michael A Caligiuri, Jianhua Yu, ...> ;Cancer Immunology Research. 2024 Apr 3
1 citations
A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors.
Sonia M Abuzakhm, Vineeth Sukrithan, Briant Fruth, Rui Qin, Jonathan Strosberg, Timothy J Hobday, Thomas Semrad, Diane Reidy-Lagunes, Hedy Lee Kindler, George P Kim, J...> ;Endocrine-Related Cancer. 2023 Nov 1
Targeted Therapies in Early-Stage Resectable Non-Small-Cell Lung Cancer: New Kids on the Block.
Jason Liu, Arya Amini, Ameish Govindarajan, Tariq Abuali, Isa Mambetsariev, Erminia Massarelli, Victoria Villaflor, Miguel Villalona-Calero, Howard West, Terence Willi...> ;JCO Precision Oncology. 2023 Sep 1
Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
Maryam Ebadi, Colton Ladbury, Jason Liu, Adam Rock, Mykola Onyshchenko, Victoria Villaflor, Miguel Villalona-Calero, Ravi Salgia, Erminia Massarelli, Percy Lee, Terenc...> ;Clinical Lung Cancer. 2023 Nov 1
1 citations
Integrating Early-Stage Drug Development with Clinical Networks; Challenges and Opportunities: The City of Hope Developing Experience.
Miguel A Villalona-Calero, Jyoti Malhotra, Vincent Chung, Yan Xing, Stacy W Gray, Heather Hampel, Stephen Gruber, Kevin McDonnell> ;Journal of Clinical Medicine. 2023 Jun 15
Order of patient entry and outcomes in phase II clinical trials: A meta-analysis of individual patient data.
Carolyn E Behrendt, Miguel A Villalona-Calero, Edward M Newman, Paul H Frankel> ;Contemporary Clinical Trials. 2023 Feb 1
3 citations
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.
Jennifer Novak, Ravi Salgia, Howard West, Miguel A Villalona-Calero, Sagus Sampath, Terence Williams, Victoria Villaflor, Erminia Massarelli, Ranjan Pathak, Marianna K...> ;Cancers. 2022 Aug 18
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors.
Miguel A Villalona-Calero, John P Diaz, Wenrui Duan, Zuanel Diaz, Eric D Schroeder, Santiago Aparo, Troy Gatcliffe, Federico Albrecht, Siddhartha Venkatappa, Victor Gu...> ;Biomarker Research. 2022 Jun 3
Disparities in Cancer Care and Scientific Knowledge in Hispanic/Latinx People in the United States.
Linda D Bosserman, Narjust Duma, Miguel Villalona-Calero, Gilberto Lopes, Pelin Cinar> ;JCO Oncology Practice. 2022 May 1
2 citations
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
Jason Liu, Emily Bratton, Xinyan Yu, Colton Ladbury, Joseph Wagner, Howard West, Erminia Massarelli, Ravi Salgia, Ranjan Pathak, Victoria Villaflor, Miguel Villalona-C...> ;American Journal of Clinical Oncology. 2022 Feb 1
Adjunctive PD-1 inhibitorstandard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
Edgar Theodore Polintan, Stephanie Krystel Canicula, Jesus Alfonso Catahay, Kevin Bryan Lo, Miguel Villalona-Calero, Herbert Ho-Fung Loong> ;Therapeutic Advances in Medical Oncology. 2022 Jan 1
15 citations
Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
Ray D. Page, Leylah Drusbosky, Hiba I. Dada, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona-Calero, Daniel Dix, Justin ...> ;Clinical Lung Cancer. 2021 Oct 10
MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers.
Wenrui Duan, Shirley Tang, Li Gao, Kathleen Dotts, Andrew Fink, Arjun Kalvala, Brittany Aguila, Qi-En Wang, Miguel A. Villalona-Calero> ;Scientific Reports. 2021 Feb 24
28 citations
Fanconi Anemia Repair Pathway Dysfunction, a Potential Therapeutic Target in Lung Cancer
Wenrui Duan, Li Gao, Brittany Aguila, Arjun Kalvala, Gregory A. Otterson, Miguel A. Villalona-Calero> ;Frontiers in Oncology. 2014 Dec 19
7 citations
The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.
Julian Ramelow, Christopher Brooks, Li Gao, Abeer A. Almiman, Terence M. Williams, Miguel A. Villalona-Calero, Wenrui Duan> ;BMC Cancer. 2020 Aug 8
8 citations
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine P...
Robert Wesolowski, Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao, Ewa Mrozek, Rachel M. Layman, Erin Macrae, Wenrui Duan, Jun Zhang, Nathan Hall, ...> ;The Oncologist. 2020 Aug 1
8 citations
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Paul K. Paik, Rachel Kim, Linda Ahn, Andrew J. Plodkowski, Ai Ni, Mark T.A. Donoghue, Philip Jonsson, Miguel A. Villalona-Calero, Kenneth K. Ng, Daniel C. McFarland, J...> ;Clinical Cancer Research. 2020 Apr 15
2 citations
Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.
Wenrui Duan, Li Gao, Arjun Kalvala, Brittany Aguila, Christopher Brooks, Xiaokui Mo, Haiming Ding, Konstantin Shilo, Gregory A. Otterson, Miguel A. Villalona-Calero> ;International Journal of Cancer. 2019 Nov 1
329 citations
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.
Natasha B. Leighl, Ray D. Page, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona-Calero, Daniel Dix, Justin I. Odegaard, ...> ;Clinical Cancer Research. 2019 Apr 15
6 citations
EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors
Fernando Vargas‐Madueno, Edwin Gould, Raul Valor, Nhu Ngo, Linsheng Zhang, Miguel A. Villalona‐Calero> ;The Oncologist. 2018 Oct 1
6 citations
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate ca...
Paul Monk, Glenn Liu, Walter M. Stadler, Susan Geyer, Ying Huang, John J. Wright, Miguel A. Villalona-Calero, James L. Wade, Russell Z. Szmulewitz, Shilpa Gupta, Amir ...> ;Investigational New Drugs. 2018 Oct 1
80 citations
Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer.
Dwight H. Owen, Lai Wei, Erin M. Bertino, Thomas Edd, Miguel A. Villalona-Calero, Kai He, Peter G. Shields, David P. Carbone, Gregory A. Otterson> ;Clinical Lung Cancer. 2018 Aug 22
96 citations
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Carl Morrison, Sarabjot Pabla, Jeffrey M. Conroy, Mary Nesline, Sean T. Glenn, Devin Dressman, Antonios Papanicolau-Sengos, Blake Burgher, Jonathan Andreas, Vincent Gi...> ;Journal for Immunotherapy of Cancer. 2018 May 9
23 citations
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitor...
Kerin B. Adelson, Bhuvaneswari Ramaswamy, Joseph A. Sparano, Paul J. Christos, John J. Wright, George Raptis, Gang Han, Miguel A. Villalona-Calero, Cynthia X. Ma, Dawn...> ;NPJ Breast Cancer. 2016 Dec 14
19 citations
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Miguel A. Villalona-Calero, Wenrui Duan, Weiqiang Zhao, Konstantin Shilo, Larry J. Schaaf, Jennifer Thurmond, Judith A. Westman, John L. Marshall, Li Xiaobai, Jiuping ...> ;Journal of the National Cancer Institute. 2016 Jul 1
Join now to see all

Press Mentions

New Advances in Treating Lung Cancer, the Deadliest CancerMay 20th, 2016

Grant Support

Targeting Somatic Homologous Recombination In Solid TumorsNational Cancer Institute2010–2012
Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2011
Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2010
Tas:: 75 0850 ::Tas Recovery ACT - Actnow Clinical Trial 8472Division Of Cancer Treatment2009
Early Therapeutics Development With Phase II EmphasisDivision Of Cancer Treatment2009
Biomodulation Of Capecitabine By Docetaxel In Non-Small*National Cancer Institute2004–2005
TNF Blockade In Pancreatic Cancer PatientsNational Cancer Institute2003–2004
Phase II Randomized Trial Of CPT-11 And Mitomycin CNational Cancer Institute2002–2003
Phase I Study Of Sequential CPT 11 &Mitomycin CNational Center For Research Resources1999–2002
Translational Research In Lung CancerNational Cancer Institute1998–2002
Phase I Study To Determine The Safety Of Ecteinascidin-743National Center For Research Resources1997–2000
Phase I Protocol To Determine The Safety Of Lu79553 As An IV Infusion Daily X 5National Center For Research Resources1998–1999
Phase I Trial Of PN401 As Rescue Agent For Escalating Doses Of 5-FUNational Center For Research Resources1997–1999
Translational Research In Lung CancerNational Cancer Institute1997–1998
Phase I Protocolto Determine The Safety Of Lu79553 As An IV Infusion Daily X 5National Center For Research Resources1997
Effect Of H Corticotropin Releasing Factor On Peritumoral BrainNational Center For Research Resources1996